Cellectis Announces Third Quarter 2025 Results
Cellectis has reported its third quarter 2025 results, highlighting progress in its clinical programs for lasmé-cel and éti-cel.
Financial Overview
According to the press release, Cellectis had $225 million in cash, cash equivalents, and term deposits as of September 30, 2025. This amount includes $4.4 million in restricted cash and $168.2 million in term deposits. The company anticipates that this cash position will fund its operations until the second half of 2027. For the nine months ending September 30, 2025, Cellectis recorded consolidated revenue of $67.4 million, up from $34.1 million for the same period in 2024. This increase is attributed to the advancement of research activities and compliance with obligations under the research agreement with AstraZeneca. Research and development expenses amounted to $69.1 million.
Clinical Program Updates
Cellectis presented clinical data for its lasmé-cel (UCART22) and éti-cel (UCART20x22) programs, aimed at treating B-cell acute lymphoblastic leukemia and relapsed or refractory non-Hodgkin lymphoma, respectively. Lasmé-cel demonstrated an overall response rate of 68% in the phase 1 BALLI-01 study. An initial interim analysis for phase 2 is scheduled for the fourth quarter of 2026. Éti-cel recorded an overall response rate of 86% in the NATHALI-01 study. Cellectis plans to share complete phase 1 results in 2026.
Strategic Partnerships and Future Plans
The company also highlighted its partnership with AstraZeneca, focused on creating new products in cellular and genomic therapy. Additionally, an arbitration decision with Servier is expected by December 15, 2025. Cellectis continues its efforts to gain approval for its flagship therapies, with a marketing authorization application for lasmé-cel planned in 2028. The company anticipates that lasmé-cel could achieve potential annual revenues of $700 million by 2035.
